Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
July 29, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
July 14, 2021 14:00 ET
|
Adial Pharmaceuticals, Inc
Data merits further testing for pain reduction as a possible alternative to opioids Validation of Purnovate acquisition CHARLOTTESVILLE, Va., July 14, 2021 (GLOBE NEWSWIRE) -- Adial...
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
July 07, 2021 10:11 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
July 06, 2021 09:25 ET
|
Adial Pharmaceuticals, Inc
Study Drug Continues to Appear to be Well-Tolerated Patient Retention Currently Exceeds Expectations CHARLOTTESVILLE, Va., July 06, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
Adial Joins Russell Microcap® Index
June 28, 2021 09:45 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Provides Regulatory and Development Update
June 24, 2021 17:07 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for...
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic Test
June 22, 2021 09:55 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 22, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the...
Adial Pharmaceuticals Comments on Article in ‘The Atlantic,’ Highlighting the Second Pandemic of Addiction
June 07, 2021 09:30 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
June 03, 2021 09:54 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...
Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Disorder
May 18, 2021 13:19 ET
|
Adial Pharmaceuticals, Inc
CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of...